Research
Hormonal
Serum from humans undergoing Alternate Day Fasting (ADF) induces in vitro cellular adaptations associated with longevity, including increased Sirt1 protein, reduced proliferation, and enhanced heat stress resistance.
If you practice Alternate Day Fasting, your body produces serum factors that may protect your cells from stress and aging markers like Sirt1. This suggests ADF is a potent tool for longevity, potentially more so than continuous mild restriction for some markers.
ModerateSupportsMEDIUM confidence
Cells cultured in serum from ADF participants, showed a 20% increase in Sirt1 protein which correlated with reduced triglyceride levels. ADF serum also induced a 9% decrease in proliferation and a 25% increase in heat resistance.
Why this rating
In vitro study using human serum; strong mechanistic signal but lacks in vivo longevity endpoints.
Source
In Vitro Cellular Adaptations of Indicators of Longevity in Response to Treatment with Serum Collected from Humans on Calorie Restricted Diets
Joanne Allard et al. · PLoS ONE · 2008
DOI 10.1371/journal.pone.0003211
mechanism_only · n=42Cited 70×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Serum from humans undergoing Continuous Calorie Restriction (CR) increases Sirt1 protein and PGC-1a mRNA levels in vitro, indicating metabolic and mitochondrial adaptations associated with longevity.Moderate
- Alternate Day Fasting (ADF) induces greater stress resistance and Sirt1 upregulation in vitro than Continuous Calorie Restriction (CR) or Control diets.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →